Cargando…

Impaired immune response drives age-dependent severity of COVID-19

Severity of COVID-19 shows an extraordinary correlation with increasing age. We generated a mouse model for severe COVID-19 and show that the age-dependent disease severity is caused by the disruption of a timely and well-coordinated innate and adaptive immune response due to impaired interferon (IF...

Descripción completa

Detalles Bibliográficos
Autores principales: Beer, Julius, Crotta, Stefania, Breithaupt, Angele, Ohnemus, Annette, Becker, Jan, Sachs, Benedikt, Kern, Lisa, Llorian, Miriam, Ebert, Nadine, Labroussaa, Fabien, Nhu Thao, Tran Thi, Trueeb, Bettina Salome, Jores, Joerg, Thiel, Volker, Beer, Martin, Fuchs, Jonas, Kochs, Georg, Wack, Andreas, Schwemmle, Martin, Schnepf, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499827/
https://www.ncbi.nlm.nih.gov/pubmed/36129445
http://dx.doi.org/10.1084/jem.20220621
Descripción
Sumario:Severity of COVID-19 shows an extraordinary correlation with increasing age. We generated a mouse model for severe COVID-19 and show that the age-dependent disease severity is caused by the disruption of a timely and well-coordinated innate and adaptive immune response due to impaired interferon (IFN) immunity. Aggravated disease in aged mice was characterized by a diminished IFN-γ response and excessive virus replication. Accordingly, adult IFN-γ receptor-deficient mice phenocopied the age-related disease severity, and supplementation of IFN-γ reversed the increased disease susceptibility of aged mice. Further, we show that therapeutic treatment with IFN-λ in adults and a combinatorial treatment with IFN-γ and IFN-λ in aged Ifnar1(−/−) mice was highly efficient in protecting against severe disease. Our findings provide an explanation for the age-dependent disease severity and clarify the nonredundant antiviral functions of type I, II, and III IFNs during SARS-CoV-2 infection in an age-dependent manner. Our data suggest that highly vulnerable individuals could benefit from immunotherapy combining IFN-γ and IFN-λ.